ERBB2 and gastroesophageal junction adenocarcinoma: Based on these pivotal findings, the US FDA approved zolbetuximab in combination with fluoropyrimidine and platinum-based chemotherapy as a first-line treatment for adult patients with HER2-negative, CLDN18.2-positive, locally advanced or metastatic gastric and GEJ adenocarcinoma.57